ALKERMES RECEIVES PATENT ON RMP TECHNOLOGY
ALKERMES RECEIVES PATENT ON RMP TECHNOLOGY CAMBRIDGE, Mass., May 14 /PRNewswire/ -- Alkermes, Inc.
(NASDAQ: ALKS) today announced that it has received U.S. patent 5,112,596 on its Receptor-Mediated Permeabilizer (RMP) technology. The claims in this patent include the use of a family of compounds to increase the permeability of the blood-brain barrier when given intravenously. Additional patent applications directed to specific chemical compositions and other aspects of the RMP technology are pending.
Alkermes is developing RMPs to be used in conjunction with therapeutic compounds for the treatment of infectious diseases of the central nervous system and brain tumor. RMP-7, the lead compound from the RMP family, is currently in phase I clinical trials to evaluate its safety and tolerability in normal volunteers. The company has completed the original protocol for its first phase I study. In this study, no dose limiting adverse experiences were observed at any of the 11 RMP-7 dose levels tested. Trials of RMP-7 in combination with a therapeutic agent in a patient population are expected to begin in late 1992. In April 1992, the company announced the closing of a $46 million research and development limited partnership, Alkermes Clinical Partners, L.P., formed to fund further clinical development of RMPs in several indications. The patent has been licensed to the partnership. "This first patent relating to our RMP technology is an important milestone for Alkermes," said Richard F. Pops, president and chief executive officer of Alkermes. "The broad coverage it provides will be of increasing importance as we continue the clinical development of RMP-7." Alkermes is a neuropharmaceutical company founded in 1987 that is focused on the development and commercialization of therapeutic and diagnostic products for the treatment of diseases and disorders of the central nervous system. -0- 5/14/92 /CONTACT: Michael J. Landine, chief financial officer of Alkermes, 617-494-0171, or Thomas A. Pearson of Pearson Communications, 215-644-4420, for Alkermes/ (ALKS) CO: Alkermes, Inc. ST: Massachusetts IN: MTC SU: ERN
TM -- NE007 -- 0276 05/14/92 13:19 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||May 14, 1992|
|Previous Article:||ADVANCED MEDICAL REPORTS FIRST QUARTER RESULTS|
|Next Article:||ONCOGENE SCIENCE REPORTS SECOND-QUARTER RESULTS|